Development of OTT166 an RGD-Binding Integrin Antagonist for the Topical Treatment of Diabetic Retinopathy
Time: 4:10 pm
day: Day One
Details:
- Distributes to posterior segment of the eye after eye drop administration
- Reduces neovascularization and vessel leakage in multiple animal models of diabetic retinopathy and wet-AMD
- Phase 1 clinical data show safety and tolerability and evidence of biological activity – proceeding to Phase 2
